CN111035631B - 乳酸钙在制备防治鲤春病毒血症病毒感染的药物中的应用 - Google Patents
乳酸钙在制备防治鲤春病毒血症病毒感染的药物中的应用 Download PDFInfo
- Publication number
- CN111035631B CN111035631B CN201911424071.3A CN201911424071A CN111035631B CN 111035631 B CN111035631 B CN 111035631B CN 201911424071 A CN201911424071 A CN 201911424071A CN 111035631 B CN111035631 B CN 111035631B
- Authority
- CN
- China
- Prior art keywords
- calcium lactate
- svcv
- cells
- virus
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 title claims abstract description 61
- 239000001527 calcium lactate Substances 0.000 title claims abstract description 61
- 229960002401 calcium lactate Drugs 0.000 title claims abstract description 61
- 235000011086 calcium lactate Nutrition 0.000 title claims abstract description 61
- 241000036569 Carp sprivivirus Species 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 230000009385 viral infection Effects 0.000 title claims description 6
- 230000014509 gene expression Effects 0.000 abstract description 26
- 241000700605 Viruses Species 0.000 abstract description 21
- 208000015181 infectious disease Diseases 0.000 abstract description 19
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 241000252212 Danio rerio Species 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 238000011529 RT qPCR Methods 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000005727 virus proliferation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 230000034512 ubiquitination Effects 0.000 description 21
- 238000010798 ubiquitination Methods 0.000 description 21
- 241000251468 Actinopterygii Species 0.000 description 18
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 238000001262 western blot Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 229910001424 calcium ion Inorganic materials 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- 101710181008 P protein Proteins 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911424071.3A CN111035631B (zh) | 2019-12-31 | 2019-12-31 | 乳酸钙在制备防治鲤春病毒血症病毒感染的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911424071.3A CN111035631B (zh) | 2019-12-31 | 2019-12-31 | 乳酸钙在制备防治鲤春病毒血症病毒感染的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111035631A CN111035631A (zh) | 2020-04-21 |
CN111035631B true CN111035631B (zh) | 2021-03-16 |
Family
ID=70243397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911424071.3A Active CN111035631B (zh) | 2019-12-31 | 2019-12-31 | 乳酸钙在制备防治鲤春病毒血症病毒感染的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111035631B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115040517B (zh) * | 2022-06-22 | 2023-05-23 | 中国科学院水生生物研究所 | 石蒜碱在防治svcv感染中的应用 |
CN115040537B (zh) * | 2022-06-22 | 2023-09-01 | 中国科学院水生生物研究所 | 锰离子在防治水生病毒感染中的应用 |
CN115025117B (zh) * | 2022-06-22 | 2023-06-20 | 中国科学院水生生物研究所 | 镁离子在防治水生病毒感染中的应用 |
CN118078790A (zh) * | 2024-03-04 | 2024-05-28 | 中国科学院水生生物研究所 | 乳酸根离子在鱼类抗病毒中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050275A (ja) * | 2006-08-22 | 2008-03-06 | Fujitsu Ltd | 病原の感染防止方法 |
-
2019
- 2019-12-31 CN CN201911424071.3A patent/CN111035631B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050275A (ja) * | 2006-08-22 | 2008-03-06 | Fujitsu Ltd | 病原の感染防止方法 |
Non-Patent Citations (1)
Title |
---|
Transcriptomic responses of S100 family to bacterial and viral infection in zebrafish;Chang Zhang等;《Fish and Shellfish Immunology》;20190920;第94卷;685-696 * |
Also Published As
Publication number | Publication date |
---|---|
CN111035631A (zh) | 2020-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111035631B (zh) | 乳酸钙在制备防治鲤春病毒血症病毒感染的药物中的应用 | |
CN110200961B (zh) | 表没食子儿茶素没食子酸酯在制备预防和/或治疗猪流行性腹泻病毒制剂中的应用 | |
CN110420331A (zh) | Alkbh5抑制物在治疗病毒感染性疾病中的应用 | |
CN106574251A (zh) | 新颖噬菌体和包括其的组合物 | |
CN101289666A (zh) | 重组猪α型干扰素的制备方法 | |
Ou et al. | Molecular cloning of the MARCH family in grass carp (Ctenopharyngodon idellus) and their response to grass carp reovirus challenge | |
CN112336708B (zh) | 替拉曲考在治疗柯萨奇病毒感染中的应用 | |
CN110251657B (zh) | Ebv brlf1及其功能性小肽在抑制炎症小体活性中的应用 | |
CN112587532B (zh) | PARP抑制剂Rucaparib在制备抗鱼类弹状病毒产品中的应用 | |
KR20090077303A (ko) | 넙치의 바이러스성 출혈성 패혈증 예방방법 및 예방 시스템 | |
CN112569233B (zh) | Parp抑制剂pj34在制备抗鱼类弹状病毒产品中的应用 | |
CN112315962B (zh) | 霉酚酸在治疗和预防柯萨奇病毒感染中的应用 | |
KR102353119B1 (ko) | 시아노박테리아 추출물, 이의 제조 방법 및 그 용도 | |
CN103751803B (zh) | 干扰素调节因子9(irf9)及其抑制剂在脑卒中疾病中的应用 | |
CN113444696A (zh) | 一种嗜水气单胞菌噬菌体及其应用 | |
CN101376879A (zh) | 表达牛干扰素(α、β或γ-干扰素)的重组新城疫LaSota弱毒疫苗株 | |
CN112294795B (zh) | 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用 | |
CN106822176B (zh) | 氯化锂抑制口蹄疫病毒的用途 | |
CN112516150B (zh) | 雷公藤三萜酸在制备防治白斑综合征病毒药物的应用 | |
CN115350170B (zh) | 牛磺酸在制备提高中华鳖抗病毒性腮腺炎病能力的药物中的应用 | |
CN110721174B (zh) | 一种用于防治鱼类粘孢子虫病的药物 | |
CN115837074B (zh) | 一种鲑鳟鱼传染性造血器官坏死病和传染性胰脏坏死病二联佐剂疫苗及其制备方法 | |
CN110462032A (zh) | 作为病毒抑制的靶标的pum1蛋白 | |
CN118356440A (zh) | 锌离子在防治水生病毒感染中的应用 | |
RU2623063C2 (ru) | Способ профилактики и лечения лейкоза крупного рогатого скота |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240131 Address after: Building 2, No. 4 Fushan 6th Road, Qianwu Town, Doumen District, Zhuhai City, Guangdong Province, 519170 Patentee after: GUANGDONG LIANKUN GROUP Co.,Ltd. Country or region after: China Patentee after: Zhuhai Yulai Yuwang Biotechnology Co.,Ltd. Address before: 430072 No. 7 South East Lake Road, Wuchang District, Hubei, Wuhan Patentee before: Institute of Hydrobiology, Chinese Academy of Sciences Country or region before: China |
|
TR01 | Transfer of patent right |